Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies

Molecular Oncology - Tập 3 - Trang 238-247 - 2009
Johan Rockberg1, Jochen M. Schwenk1, Mathias Uhlén1
1School of Biotechnology, Royal Institute of Technology (KTH), AlbaNova University Center, SE-106 91 Stockholm, Sweden

Tóm tắt

Antibodies have become valuable therapeutic agents for targeting of extracellular proteins in various diseases, including cancer, autoimmunity and cardiovascular disorders. For breast cancer, antibodies targeting the human HER2 have been shown to result in cell growth inhibition both in vitro and in patients with breast tumors. There is evidence to suggest that targeting multiple HER2 epitopes may result in increased growth inhibition making it interesting to find antibodies targeting new epitopes. Here, we report on a new scheme to discover antibodies directed to new epitopes using the extracellular domain of the HER2 as a model. Polyclonal antibodies were generated using recombinant protein fragments and affinity purified fractions of the antibodies were functionally characterized and precisely epitope mapped using bacterial surface display. Polyclonal antibodies towards a 127 amino acid recombinant protein fragment spanning between domains II and III of the HER2 were shown to bind to human ductal carcinoma cell line BT474 resulting in growth inhibition. Affinity purification demonstrated that antibodies to two separate regions from the N‐ and C‐terminal end of the fragment exhibited the growth inhibition. Epitope mapping of the C‐terminal antibodies revealed a 25 amino acid region (LPESFDGDPASNTAPLQPEQLQVF) with two distinct epitopes mediating efficient growth inhibition. The results suggest that antibodies directed towards this region of domain III of the HER2, distinct from the well‐known monoclonal antibodies trastuzumab and pertuzumab, bind to the HER2 on living cells and exhibit growth inhibition. The work describes a new strategy to develop antibodies directed to non‐overlapping epitopes and shows a path of pursuit to explore the epitope space of a target protein.

Tài liệu tham khảo

10.1016/j.chroma.2004.06.008 10.1016/S1535-6108(02)00097-1 10.1016/j.molonc.2007.01.003 10.1073/pnas.89.10.4285 10.1038/nature01392 10.1016/S1535-6108(04)00083-2 Gelmon K. Fumoleau P. Verma S. Wardley A. Conte P.F. Miles D. Gianni L. McNally V.A. Ross G.A. Baselga J. 2008. Results of a Phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. Proceedings from ASCO 2008 Abs TBC. 10.2307/1390807 10.1016/j.jim.2006.07.014 10.2144/05385ST02 10.1016/j.tibtech.2007.07.005 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E 10.1158/0008-5472.CAN-03-3856 10.1038/ncponc0509 10.1002/pmic.200500072 10.1053/j.seminoncol.2006.04.004 Pal S.K., 2007, HER2 targeted therapy in breast cancer … beyond Herceptin. Rev. Endocr. Metab, Disord, 8, 269 10.1158/0008-5472.CAN-06-2363 10.1038/ncponc1090 10.1158/1078-0432.CCR-07-4636 10.1038/nmeth.1272 10.1126/science.281.5375.363 10.1126/science.2992090 10.1074/mcp.T600035-MCP200 10.1002/jcb.20536 10.1126/science.3798106 Spiridon C.I., 2002, Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo, Clin. Cancer Res., 8, 1720 10.1038/35052073
Thông tin
Thông tin xuất bản

Molecular Oncology

Tập 3

238-247

Thông tin tác giả